Checked.be
Active
BE 0739.549.477Private limited company
Axepharma
Beverhoutsveldstraat 64 ·8730 Beernem, Belgium· 6 yrs active
Sector: Detailhandel in farmaceutische producten
(47730)
Conclusion
The computed 12-month bankruptcy probability of Axepharma is 1.7% (moderate). The 2025 annual accounts show equity of €310k and a net result of €66k. Equity is growing by ~9.1% per year across the filed fiscal years. The company has been active since 2019 and the Belgian State Gazette contains no insolvency or warning signals.
Based on the State Gazette, CBE and 3 annual accounts.
Key figures
| Equity | €310k |
| Net result | €66k |
| Staff (FTE) | 1.1 |
| Active | 6 yrs |
Financial profile
96
/ 100
Exceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
Health
100
Profitability
100
Solvency
100
Growth
78
Stability
100
Bankruptcy probability (12 mo)
Risk Assessment
0 / 100
Low riskTrust signals
More than 3 years active
Founded in 2019, past the statistically most fragile first 3 years.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Checked score
100
/ 100
Excellent
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.
See plans →Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.
Financial overview
Annual accounts filed on 26-05-2026 with the NBB · fiscal year 2025 · abbreviated schema
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing
Equity: growth of ~9.1%/year over 3 fiscal years, indicative, assuming unchanged policy.
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
€98k
+11.2%
23-25
€66k
+12.8%
23-25
€68k
+11.9%
23-25
€442k
+13.7%
23-25
€310k
+0.1%
23-25
€303k
-0.7%
23-25
1
-45.0%
23-25
€49k
-6.1%
23-25
€17k
+8.1%
23-25
€63k
-
23-25
€132k
+67.3%
23-25
€130k
+69.1%
23-25
€2k
-
23-25
3.32
-33.0%
23-25
2.28
-31.1%
23-25
70.1%
-12.0%
23-25
0.43
+67.1%
23-25
21.2%
+12.7%
23-25
14.8%
-0.8%
23-25
6.94
+8.1%
23-25
Figures by fiscal year and ratios
| Fiscal year | 2025 |
|---|---|
| Deposit | abbreviated schema |
| Revenue | - |
| EBITDA | €98k |
| Net profit | €66k |
| Cash flow | €68k |
| Staff costs | €49k |
| Income taxes | €17k |
| Dividends | €63k |
| Total assets | €442k |
| Equity | €310k |
| Debt | €132k |
| of which ≤ 1y | €130k |
| of which > 1y | - |
| Working capital | €303k |
| Employees (FTE) | 1.1 |
Ratios (computed)
| 2025 | |
|---|---|
| Current ratio | 3.32 |
| Quick ratio | 2.28 |
| Working capital ratio | 68.6% |
| Solvency | 70.1% |
| Debt / equity | 0.43 |
| Long-term debt ratio | - |
| Interest coverage | 6.94 |
| Gross margin | - |
| Net margin | - |
| ROA | 14.8% |
| ROE | 21.2% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
This table shows the latest fiscal year. 2 prior years, with figures and ratios, belong to a paid plan.
See plans →
Balance-sheet composition 2025
Full annual accounts (23 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €442k |
| Fixed assets | 21/28 | €8k |
| Tangible fixed assets | 22/27 | €8k |
| Financial fixed assets | 28 | €200 |
| Current assets | 29/58 | €434k |
| Stocks & contracts in progress | 3 | €136k |
| Amounts receivable within one year | 40/41 | €104k |
| Cash & bank | 54/58 | €178k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €442k |
| Equity | 10/15 | €310k |
| Contributions / capital | 10/11 | €10k |
| Reserves | 13 | €300k |
| Amounts payable | 17/49 | €132k |
| Amounts payable within one year | 42/48 | €130k |
| Trade debts payable within one year | 44 | €41k |
| Income statement | ||
| Gross operating margin | 9900 | €152k |
| Operating result | 9901 | €96k |
| Financial income | 75 | €1k |
| Financial charges | 65 | €14k |
| Result before taxes | 9903 | €83k |
| Income taxes | 67/77 | €17k |
| Net result for the period | 9904 | €66k |
| Result to be appropriated | 9905 | €66k |
Legal Structure
| NACE primary | Detailhandel in farmaceutische producten(47730) |
| Legal form | Private limited company(610) |
| Incorporation | 12-12-2019 |
| Status | Active |
| Postal code | 8730 |
Establishment units
Axepharma
since 20192.296.535.970
Real-estate footprint
Flanders
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 31021G0511/00E000 | Flanders | 891 m² | 1 · 241 m² | 7.6 m · 1 fl. |
| 31804D1566/00B000 | Flanders | 82 m² | 1 · 81 m² | 12.8 m · 4 fl. |
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates
2026
26-05-2026 NBB filing Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
01-07-2025 NBB filing Annual accounts filed
fiscal year 2024 · micro schema
2024
31-07-2024 NBB filing Annual accounts filed
fiscal year 2023 · micro schema
2023
07-08-2023 NBB filing Annual accounts filed
fiscal year 2022 · micro schema
2022
28-07-2022 NBB filing Annual accounts filed
fiscal year 2021 · micro schema
2021
22-07-2021 NBB filing Annual accounts filed
fiscal year 2020 · micro schema
Credit advice
Company registry (CBE)
Activities
Detailhandel in farmaceutische producten47730
Names & trade names
| Legal nameNL | Axepharma |
Similar companies
Apotheek De Melkerij
BE 0758.508.524 · Beernem
APOTHEEK DESSEIN
BE 0419.948.533 · Beernem
APOTHEEK NOTEBAERT
BE 0461.051.985 · Beernem
Apotheek Wyseur
BE 0457.863.556 · Beernem
Apotheker nodig
BE 1025.896.546 · Beernem